Recent blog posts
LAPIX Therapeutics Inc. reports FDA has approved their IND application for LPX-TI641, designed to treat for Multiple Sclerosis
Latest Hotspot
4 min read
LAPIX Therapeutics Inc. reports FDA has approved their IND application for LPX-TI641, designed to treat for Multiple Sclerosis
26 September 2023
LAPIX Therapeutics, Inc. announced U.S. FDA clearance of its IND application. The approval enables Phase 1 trials for its leader compound, LPX-TI641, aimed at treating multiple sclerosis.
Read →
Revolution Medicines initiates dosing in Phase 1/1b clinical study for RMC-9805, an orally administered, covalent, mutant-specific KRASG12D inhibitor
Latest Hotspot
3 min read
Revolution Medicines initiates dosing in Phase 1/1b clinical study for RMC-9805, an orally administered, covalent, mutant-specific KRASG12D inhibitor
26 September 2023
Revolution Medicines, Inc. has initiated Phase 1/1b trials for RMC-9805, a covalent, oral KRAS G12D inhibitor for RAS-dependent cancers and the first patient already dosed targeting KRAS G12D mutation-driven cancers.
Read →
Cerevance doses first participant for CVN293 in the Phase 1 Clinical Trial, to potentially treat ALS and Alzheimer's Disease
Latest Hotspot
3 min read
Cerevance doses first participant for CVN293 in the Phase 1 Clinical Trial, to potentially treat ALS and Alzheimer's Disease
25 September 2023
Cerevance announced the start of their Phase 1 trial, with the first participant dosed to evaluate the safety, tolerability, and pharmacokinetics of CVN293.
Read →
The first participant in ImmPACT Bio's Phase 1/2 study has received treatment with IMPT-314, aimed at combatting aggressive B-cell Lymphoma
Latest Hotspot
3 min read
The first participant in ImmPACT Bio's Phase 1/2 study has received treatment with IMPT-314, aimed at combatting aggressive B-cell Lymphoma
25 September 2023
ImmPACT Bio USA, Inc has publicized that the initial patient has received treatment in the Phase 1/2 trial of IMPT-314.
Read →
MRM Health showcases encouraging findings from its Phase 2a Clinical Trial of MH002 for Ulcerative Colitis
Latest Hotspot
3 min read
MRM Health showcases encouraging findings from its Phase 2a Clinical Trial of MH002 for Ulcerative Colitis
22 September 2023
MRM Health NV has announced encouraging preliminary outcomes from its Phase 2a clinical study of MH002 against mild-to-moderate Ulcerative Colitis.
Read →
Patient Receives First Dose of ALPK1 Inhibitor, DF-003, in Drug Farm's Phase 1 Clinical Trial
Latest Hotspot
3 min read
Patient Receives First Dose of ALPK1 Inhibitor, DF-003, in Drug Farm's Phase 1 Clinical Trial
22 September 2023
Drug Farm, currently in the clinical phase, has shared the news of the first participant in the Phase 1 clinical experiment, testing DF-003, receiving their initial dosage.
Read →
The Abelacimab AF study was early terminated by the Data Monitoring Committee due to a major decline in bleeding compared to a DOAC
Latest Hotspot
3 min read
The Abelacimab AF study was early terminated by the Data Monitoring Committee due to a major decline in bleeding compared to a DOAC
22 September 2023
The study on Atrial Fibrillation using Abelacimab was prematurely ended by the Data Monitoring Committee due to a massive decrease in bleeding compared to a DOAC.
Read →
LinKinVax and Gustave Roussy confirmed the initiation of dosage in the Phase I/IIa HPV.DCVax clinical trial for HPV-positive Oropharyngeal Cancer
Latest Hotspot
3 min read
LinKinVax and Gustave Roussy confirmed the initiation of dosage in the Phase I/IIa HPV.DCVax clinical trial for HPV-positive Oropharyngeal Cancer
22 September 2023
LinKinVax and Gustave Roussy have reported that Gustave Roussy is treating the initial participant in a Phase I/IIa clinical trial using CD40HVac.
Read →
The FDA receives Lantern Pharma's IND, paving the way to Initiate Phase 1 trials for LP-284 in Non-Hodgkin’s Lymphomas
Latest Hotspot
3 min read
The FDA receives Lantern Pharma's IND, paving the way to Initiate Phase 1 trials for LP-284 in Non-Hodgkin’s Lymphomas
22 September 2023
Artificial intelligence-focused Lantern Pharma Inc unveiled the FDA's approval of their IND application for LP-284.
Read →
Otsuka and Astex declare the European Commission's authorization of INAQOVI® (oral decitabine and cedazuridine) to treat myeloid leukaemia
Latest Hotspot
3 min read
Otsuka and Astex declare the European Commission's authorization of INAQOVI® (oral decitabine and cedazuridine) to treat myeloid leukaemia
22 September 2023
Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. announced EC's approval of INAQOVI® for treating newly diagnosed acute myeloid leukaemia in adults unfit for standard induction chemotherapy.
Read →
Atamyo Therapeutics, known as ATA-200, designed to treat Limb-Girdle Muscular Dystrophy Type 2C/R5, achieves significant progress
Latest Hotspot
3 min read
Atamyo Therapeutics, known as ATA-200, designed to treat Limb-Girdle Muscular Dystrophy Type 2C/R5, achieves significant progress
22 September 2023
Atamyo Therapeutics made public its submission of a CTA for ATA-200 in European territories.
Read →
BeiGene reports positive regulatory developments in Europe and the U.S., following the recent reacquisition of worldwide rights to TEVIMBRA®
Latest Hotspot
4 min read
BeiGene reports positive regulatory developments in Europe and the U.S., following the recent reacquisition of worldwide rights to TEVIMBRA®
22 September 2023
BeiGene, Ltd. revealed that TEVIMBRA®(tislelizumab) has received approval by the EC to be used as a single therapy for addressing unresectable.
Read →